|
🐜
|
Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma.
21 auth.
R. Finn,
S. Qin,
M. Ikeda,
P. Galle,
M. Ducreux,
Tae-You Kim,
M. Kudo,
V. Breder,
P. Merle,
A. Kaseb,
...
Daneng Li,
W. Verret,
Derek-Zhen Xu,
Sairy G. Hernandez,
Juan Liu,
Chen Huang,
S. Mulla,
Yulei N. Wang,
Ho Yeong Lim,
A. Zhu,
A. Cheng
|
12 |
2020 |
12
🐜
|
|
🐜
|
Updated efficacy and safety data from IMbrave150: atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma.
19 auth.
A. Cheng,
S. Qin,
M. Ikeda,
P. Galle,
M. Ducreux,
Tae-You Kim,
Ho Yeong Lim,
M. Kudo,
V. Breder,
P. Merle,
...
A. Kaseb,
Daneng Li,
W. Verret,
N. Ma,
A. Nicholas,
Yifan Wang,
Lindong Li,
A. Zhu,
R. Finn
|
9 |
2021 |
9
🐜
|
|
🐜
|
NASH limits anti-tumour surveillance in immunotherapy-treated HCC
110 auth.
D. Pfister,
N. Núñez,
R. Pinyol,
O. Govaere,
M. Pinter,
M. Szydlowska,
Revant Gupta,
Mengjie Qiu,
A. Deczkowska,
A. Weiner,
F. Müller,
A. Sinha,
Ekaterina Friebel,
T. Engleitner,
Daniela Lenggenhager,
...
A. Moncsek,
D. Heide,
Kristin Stirm,
Jan Kosla,
E. Kotsiliti,
V. Leone,
M. Dudek,
Suhail Yousuf,
Donato Inverso,
I. Singh,
A. Teijeiro,
F. Castet,
C. Montironi,
Philipp K. Haber,
D. Tiniakos,
P. Bedossa,
S. Cockell,
R. Younes,
M. Vacca,
F. Marra,
J. Schattenberg,
M. Allison,
E. Bugianesi,
V. Ratziu,
T. Pressiani,
A. D’Alessio,
N. Personeni,
L. Rimassa,
A. Daly,
B. Scheiner,
K. Pomej,
M. Kirstein,
A. Vogel,
M. Peck‐Radosavljevic,
F. Hucke,
F. Finkelmeier,
O. Waidmann,
J. Trojan,
K. Schulze,
H. Wege,
S. Koch,
A. Weinmann,
M. Bueter,
F. Rössler,
A. Siebenhüner,
S. De Dosso,
Jan-Philipp Mallm,
V. Umansky,
M. Jugold,
T. Luedde,
A. Schietinger,
P. Schirmacher,
B. Emu,
H. Augustin,
A. Billeter,
B. Müller-Stich,
H. Kikuchi,
D. Duda,
F. Kütting,
D. Waldschmidt,
M. Ebert,
N. Rahbari,
H. Mei,
A. Schulz,
M. Ringelhan,
N. Malek,
S. Spahn,
M. Bitzer,
M. Ruiz de Galarreta,
A. Lujambio,
J. Dufour,
T. Marron,
A. Kaseb,
M. Kudo,
Yi‐Hsiang Huang,
N. Djouder,
Katharina Wolter,
L. Zender,
P. Marche,
T. Decaens,
D. Pinato,
R. Rad,
J. Mertens,
A. Weber,
K. Unger,
F. Meissner,
S. Roth,
Z. Jílková,
M. Claassen,
Q. Anstee,
I. Amit,
P. Knolle,
B. Becher,
J. Llovet,
M. Heikenwalder
|
9 |
2021 |
9
🐜
|
|
🐜
|
Systemic Therapy for Advanced Hepatocellular Carcinoma: ASCO Guideline.
27 auth.
J. Gordan,
E. Kennedy,
G. Abou-Alfa,
M. Beg,
S. Brower,
T. Gade,
L. Goff,
Shilpi Gupta,
J. Guy,
W. Harris,
R. Iyer,
I. Jaiyesimi,
M. Jhawer,
A. Karippot,
A. Kaseb,
...
R. Kelley,
J. Knox,
J. Kortmansky,
A. Leaf,
William M. Remak,
R. Shroff,
D. Sohal,
T. Taddei,
N. Venepalli,
Andrea Wilson,
A. Zhu,
M. Rose
|
8 |
2020 |
8
🐜
|
|
🐜
|
Gemcitabine, Cisplatin, and nab-Paclitaxel for the Treatment of Advanced Biliary Tract Cancers: A Phase 2 Clinical Trial.
13 auth.
R. Shroff,
M. Javle,
Lianchun Xiao,
A. Kaseb,
G. Varadhachary,
R. Wolff,
K. Raghav,
M. Iwasaki,
P. Masci,
R. Ramanathan,
...
D. Ahn,
T. Bekaii-Saab,
M. Borad
|
8 |
2019 |
8
🐜
|
|
🐜
|
Biliary cancer: Utility of next‐generation sequencing for clinical management
19 auth.
M. Javle,
T. Bekaii-Saab,
A. Jain,
Ying Wang,
R. Kelley,
Kai Wang,
H. Kang,
D. Catenacci,
Siraj M. Ali,
S. Krishnan,
...
D. Ahn,
A. G. Bocobo,
M. Zuo,
A. Kaseb,
V. Miller,
P. Stephens,
F. Meric-Bernstam,
R. Shroff,
Jeffrey Ross
|
8 |
2016 |
8
🐜
|
|
🐜
|
Association of diabetes duration and diabetes treatment with the risk of hepatocellular carcinoma
11 auth.
Manal M. Hassan,
S. Curley,
Donghui Li,
A. Kaseb,
M. Davila,
E. Abdalla,
...
M. Javle,
Dalia M. Moghazy,
R. Lozano,
J. Abbruzzese,
J. Vauthey
|
8 |
2010 |
8
🐜
|
|
🐜
|
Phase II trial of the combination of bevacizumab and erlotinib in patients who have advanced hepatocellular carcinoma.
10 auth.
M. Thomas,
Jeffrey S. Morris,
Romil Chadha,
M. Iwasaki,
H. Kaur,
Elinor Lin,
...
A. Kaseb,
K. Glover,
M. Davila,
J. Abbruzzese
|
8 |
2009 |
8
🐜
|
|
🐜
|
Molecular correlates of clinical response and resistance to atezolizumab in combination with bevacizumab in advanced hepatocellular carcinoma
20 auth.
A. Zhu,
Alexander R. Abbas,
Marina Ruiz de Galarreta,
Y. Guan,
Shan Lu,
H. Koeppen,
Wenjun Zhang,
Chih-Hung Hsu,
A. He,
B. Ryoo,
...
T. Yau,
A. Kaseb,
Adam M. Burgoyne,
F. Dayyani,
J. Spahn,
W. Verret,
R. Finn,
H. Toh,
A. Lujambio,
Yulei N. Wang
|
8 |
2022 |
8
🐜
|
|
🐜
|
Cabozantinib plus atezolizumab versus sorafenib for advanced hepatocellular carcinoma (COSMIC-312): a multicentre, open-label, randomised, phase 3 trial.
22 auth.
R. Kelley,
L. Rimassa,
A. Cheng,
A. Kaseb,
S. Qin,
A. Zhu,
S. Chan,
T. Melkadze,
W. Sukeepaisarnjaroen,
V. Breder,
...
G. Verset,
E. Gane,
I. Borbath,
J. D. G. Rangel,
B. Ryoo,
T. Makharadze,
P. Merle,
F. Benzaghou,
Kamalika Banerjee,
S. Hazra,
J. Fawcett,
T. Yau
|
8 |
2022 |
8
🐜
|
|
🐜
|
Antitumor activity of gemcitabine and oxaliplatin is augmented by thymoquinone in pancreatic cancer.
8 auth.
Sanjeev Banerjee,
A. Kaseb,
Zhiwei Wang,
D. Kong,
Mussop Mohammad,
S. Padhye,
...
F. Sarkar,
R. Mohammad
|
7 |
2009 |
7
🐜
|
|
🐜
|
Ablative Radiotherapy Doses Lead to a Substantial Prolongation of Survival in Patients With Inoperable Intrahepatic Cholangiocarcinoma: A Retrospective Dose Response Analysis.
14 auth.
R. Tao,
S. Krishnan,
P. Bhosale,
M. Javle,
T. Aloia,
R. Shroff,
A. Kaseb,
A. Bishop,
C. Swanick,
E. Koay,
...
H. Thames,
T. Hong,
P. Das,
C. Crane
|
7 |
2016 |
7
🐜
|
|
🐜
|
IL-6/JAK1 pathway drives PD-L1 Y112 phosphorylation to promote cancer immune evasion.
29 auth.
Li-Chuan Chan,
Chia‐Wei Li,
W. Xia,
Jung-Mao Hsu,
Heng-Huan Lee,
Jong-Ho Cha,
Hung-Ling Wang,
Wen-Hao Yang,
Er-Yen Yen,
Wei-Chao Chang,
Zhengyu Zha,
Seung-Oe Lim,
Yun-Ju Lai,
Chunxiao Liu,
Jielin Liu,
...
Q. Dong,
Yi Yang,
Lin-lin Sun,
Yongkun Wei,
L. Nie,
J. Hsu,
Hui Li,
Qi Ye,
Manal M. Hassan,
H. Amin,
A. Kaseb,
Xin Lin,
Shao-Chun Wang,
M. Hung
|
7 |
2019 |
7
🐜
|
